-+ 0.00%
-+ 0.00%
-+ 0.00%

MindMaze Therapeutics' H1 Net Loss Widens; Total Revenue Rises

MT Newswires·08/27/2026 01:21:01
Listen to the news
01:21 AM EDT, 08/27/2026 (MT Newswires) -- MindMaze Therapeutics (MMTX.SW) said Thursday that net loss for the first half widened, while total revenue increased year over year. Net loss for the six months ended June 30 was 6.9 million francs, compared with 3.3 million francs earlier. Loss per share moved to 0.0450 franc from 0.262 franc. The Swiss neurotherapeutics company's total revenue was 586,000 francs compared with 32,000 francs a year ago.